NCT01341834View on ClinicalTrials.gov

Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

June 30, 2016

Study Completion Date

December 31, 2018

Conditions
Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour
Interventions
DRUG

LBH589 and RAD001

Dose escalation of LBH589 tablets (5 and 10 mg) and RAD001 tablets (2.5, 5 mg and 10mg)

Trial Locations (1)

169690

National Cancer Center Singapore, Singapore

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

National Cancer Centre, Singapore

OTHER